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Key Points
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We conducted a prospective randomized trial to assess hemoglobin (Hb) response to
recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell trans-
plantation (HCT). Patients (N5 131) were randomized (1:1) between no treatment (control
arm) or erythropoietin at 500 U/kg per week (EPO arm). Patients were also stratified into
3 cohorts: patients undergoing myeloablative HCT with rhEPO to start on day (D)28,
patients given nonmyeloablative HCT (NMHCT) with rhEPO to start on D28, and patients
also given NMHCT but with rhEPO to start on D0. The proportion of complete correctors
(ie, Hb ‡13 g/dL) before D126 posttransplant was 8.1% in the control arm (median not
reached) and 63.1% in the EPO arm (median, 90 days) (P < .001). Hb levels were higher and transfusion requirements decreased
(P< .001) in the EPOarm, but not during the firstmonth in the nonmyeloablative cohort starting rhEPOonD0. Therewasnodifference
in rates of thromboembolic events or other complications between the 2 arms. This is the first randomized trial to demonstrate that
rhEPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT.
There was no benefit to start rhEPO earlier after NMHCT. (Blood. 2014;124(1):33-41)
Introduction
Erythropoiesis is regulated by erythropoietin (Epo), with serum Epo
levels increasing exponentially when an anemia develops.1,2 After
high-dose chemotherapy, serum Epo rapidly increases to dispropor-
tionately high levels for 1 to 3 weeks, with a peak in the week after
conditioning.3,4 However, after myeloablative (MA) allogeneic
hematopoietic cell transplantation (HCT), Epo response to anemia
then becomes impaired: Epo levels increase in absolute terms but not
enough for the degree of anemia, resulting in inappropriately low
Epo levels and prolonged anemia.4 However, serum Epo levels
remain adequate throughout the posttransplant course after non-
myeloablative HCT (NMHCT).5
Epo expands erythropoiesis mainly by preventing apoptosis
of erythroid progenitors and proerythroblasts.6 Epo is therefore
unlikely to increase red blood cell (RBC) production when
endogenous Epo is elevated and progenitors are already surviving
and differentiating. Previous trials of recombinant human Epo
(rhEPO) afterHCThave administered very high doses of intravenous
(IV) rhEPO (usually .1000 U/kg per week) starting on day (D)1
and continuing for 1 to 2 months or until erythroid engraftment,
and they have shown little beneﬁt with a prohibitive cost.7-12
Therefore, soaking patients with huge doses of rhEPO, when the
erythroid marrow has not developed enough erythroid precursors
and endogenous Epo levels are appropriate or excessive for the
degree of anemia, may not be ideal.
We previously showed in a pilot study that rhEPO could be
very efﬁcient when rhEPO therapy was started 35 days after
MA allogeneic HCT at 500 U/kg per week.13 The hemoglobin
(Hb) response rate was .90%. Moreover, the same weekly dose
of rhEPO was as effective when given once weekly or in 3 divided
doses.14
We also carried out a pilot trial of rhEPO therapy in patients
undergoing NMHCT.15 A ﬁrst group started rhEPO on D0 and
a second started on D28 after transplantation. Compared with
historical controls, Hb values were higher but transfusion require-
ments were decreased only in the ﬁrst month in patients receiving
rhEPO from D0. Therefore, rhEPO therapy also appeared to be
efﬁcient after NMHCT, but less so after conventional HCT. This
prompted us to conduct a randomized trial to assess Hb response and




Patients underwent allogeneic transplantation for malignant or nonmalignant
diseases after conventional or nonmyeloablative conditioning. Patients were
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eligible if they did not have terminal organ failure, had sufﬁcient iron stores
(serum ferritin.100 mg/L), and had adequate marrow recovery (neutrophils
.13 109/L and platelet transfusion independence). Patients who underwent
2 allogeneic HCT (for rejection or relapse) could be included twice and were
considered as “separate subjects” for analyses. They received peripheral
blood stem cell (PBSC) or marrow (not cord blood) transplantation and
the graft was unmanipulated or T-cell depleted. Posttransplant immuno-
suppression was based on cyclosporine A or tacrolimus (6 other agents).
Exclusion criteria included HIV seropositivity; known allergy to rhEPO
or IV iron; evidence of active hemorrhage, hemolysis, vitamin B12 or folate
deﬁciency; or uncontrolled infection, arrhythmia, or hypertension. In these
cases, inclusion into the protocol could be delayed up to 14 days if the problem
was resolved. Patientswith aHb level.13g/dL at treatment initiationwere also
excluded.
Between D21 and D28 posttransplant if they were scheduled to start
rhEPO on D28, or before transplantation if they were scheduled to start on
D0, patients signed informed consents and were randomized 1:1 between
the control and EPO arms on the same day. There was no death or dropout
between randomization and start of the study. Patients were stratiﬁed for
the type of conditioning (MA vs non-MA) and for the start (D0 or D28) of
rhEPO therapy for NMHCT. Hence, we had 3 cohorts: the ﬁrst cohort
included patients undergoing MA HCT with rhEPO to be started on D28,
the second cohort patients given NMHCT with rhEPO to be started on
D28, and the third cohort patients undergoing NMHCT with rhEPO to be
started on D0. Based on our pilot studies in the MA13 and non-MA15
settings, we calculated that we needed 118 evaluable patients to have a 90%
power to detect a signiﬁcance level of 0.05, a difference in the primary end
points of 75%, 50%, and 45% in the MA, non-MA D28, and non-
myeloablative D0 cohorts, respectively. The study started with the ﬁrst 2
cohorts only, to which patients were assigned on the basis of their
conditioning (MAvs non-MA), all starting rhEPOonD28.When the results
of our pilot rhEPO trial after NMHCT became available,15 we added
through an amendment the third cohort (NMHCT with rhEPO from D0)
that was scheduled to start only when recruitment in cohort 2 (NMHCT
with rhEPO from D28) was completed. Study procedures remained
otherwise identical. Randomization was carried out by following up
a computer-generated randomization list, unavailable to clinical inves-
tigators, for each cohort.
Patients (or his/her guardian if of minor age) signed an informed consent
for the clinical study, as well as to collect and analyze blood samples, and
the study was approved by the Ethics Committee of the University of Lie`ge
under number 2003/59. The study was conducted in accordance with the
Declaration of Helsinki.
RhEPO therapy
RhEPO(Neorecormon,Roche)was administered subcutaneously at 500U/kg
once per week. RhEPO doses were never raised above 500 U/kg/week. The
ﬁrst dose was given on D28, except in the third cohort (D0). Once the target
Hb level (13 g/dL) was attained, the dose of rhEPOwas reduced by half. If the
Hb increased to .14 g/dL, rhEPO was withheld and resumed at the dose of
250 U/kg per week when the Hb level decreased to,13 g/dL. If the Hb level
decreased to,12 g/dL, the dose of rhEPO was again increased to 500 U/kg
perweek.Maximumdoses of 163500U/kg perweekwere to be administered.
Maintenance with the lowest possible dose of rhEPO was allowed after
D126. Treatment was stopped in case of disease relapse.
In the EPO arm, if patients had evidence of functional iron deﬁciency
(Tsat ,20%), they received 300 mg IV iron saccharate (Venofer) on 2
consecutive visits at least one week apart. Iron therapy was repeated if
functional iron deﬁciency persisted. Iron was omitted in patients with
severe iron overload (serum ferritin.2500mg/L without inﬂammation or
liver necrosis). Control patients never received IV iron. One RBC unit
was transfused if the Hb value was between 7.0 and 7.9 g/dL, and 2 units
were transfused when it was,7 g/dL. Platelets were transfused if needed
per the institution’s standards.
Laboratory analyses
Laboratory data were monitored weekly from the day of the transplant (D0)
until D28, and then every other week. Complete blood counts, percentage and
absolute reticulocyte counts, serum Epo levels, serum soluble transferrin
receptor (sTfR) (a quantitativemeasure of total erythropoietic activity), serum
iron, Tsat, and ferritin were measured as previously reported.5,13,14,16-18
Figure 1. Flow diagram.
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Study end points
The primary end points were the median time to achieve a Hb level$13 g/dL
and proportion of complete correctors (reaching Hb$13 g/dL) beforeD126
(ie, after 14 weeks of treatment). Secondary end points included median
time to increase Hb by $2 g/dL; the proportion of responders (ie, patients
increasing Hb by $2 g/dL) and correctors (ie, patients reaching Hb $12 g/dL)
before D126; the proportion of patients requiring RBC transfusions and
the total number of RBC transfusions between D28 and D126; the area
under the curve (AUC) of Hb between D28 and D126 after transplantation;
the mean Hb values on D42, D60, D80, D100, and D126; and the mean
change in quality of life (QOL) measurements. QOL evaluations were
carried out at baseline (D28 or D0 for the 3rd cohort) as well as on D30,
D70, and D150 after rhEPO initiation based on the validated Functional
Assessment of Cancer Therapy (FACT)-anemia questionnaire.19 All
analyses were planned for the whole study population as well as for all
3 cohorts separately.
Statistical analyses
Median times from rhEPO initiation to events were assessed using
cumulative incidence methods and compared by the log-rank test. These
end points were also calculated from D28 posttransplant for control
patients (or from D0 in the third cohort). Patients were censored at the
time of graft rejection, severe autoimmune hemolysis, aplasia induced by
chemotherapy or radiotherapy, and/or disease progression. For censored
patients, the last Hb value before censure was carried forward. Numbers
of transfusions, QOL scores, andHb, reticulocyte, sTfR, Tsat, and ferritin
levels were compared using the Mann-Whitney U test. AUCs of Hb were
calculated from D28 to D126 post-HCT (14 weeks of treatment). Two-
way analysis of variance was used to analyze the impact of treatment
group and time point (D0 vs D30 vs D70 vs D150 post-rhEPO) on QOL
scores. Correlations between QOL and Hb levels were assessed with the
Spearman test. Results are presented as means and standard deviations or
numbers and percentages. To assess relapse risks, univariate and multi-
variate Cox regression models (including disease risk index, treatment
arm, and conditioning) were performed. Statistical analyses were carried
out with Graphpad Prism (Graphpad Software, San Diego, CA) and SAS,




We included 131 patients between May 2003 and January 2008.
Twelve patients were found to be ineligible: 4 in the control arm
(cord blood HCT [n5 1]), platelet transfusion dependence (n5 1),
ferritin,100 mg/L [n5 2]) and 8 in the EPO arm (cord blood HCT
[n5 2], platelet transfusion dependence ]n5 2], relapse [n5 1], late
randomization [n5 1], high baseline Hb [n5 1], assignment to the
wrong arm [n 5 1]) (Figure 1). Characteristics of the 119 patients
evaluable for efﬁcacy are detailed in Table 1. These characteristics
were comparable between arms, except for cytomegalovirus (CMV)
status (P 5 .0179). Graft composition and speed of engraftment
(slower after MA conditioning) were not signiﬁcantly different
between the 2 arms overall and in the different cohorts (supplemental
Table 1, available on the BloodWeb site).
Treatments
No patient in the control arm received rhEPO. Treatment initiation
was delayed by 1week in 6 patients and by 2weeks in 4 patients. The
total number of rhEPO injections until D126 was 12.6 6 4.6. The
most usual dose was between 30 000 U and 40 000 U (1 injection
of 30 000 U [0.6 mL] and 1 injection of 10 000 U [0.6 mL]) per
week. One patient undergoing NMHCT with rhEPO started on D0
stopped on D61 (after 10 doses) because of inefﬁcacy in the con-
text of infection and major ABO mismatch. Moreover, 19 patients
received maintenance therapy after D126.
Primary end points
Median times to achieve a Hb value$13 g/dL were undetermined in
the control arm and 90 days in the EPO arm (P, .001) (Figure 2A).
The difference remained highly signiﬁcant (P , .001) when only
patientswith baselineHbvalues,10 g/dLwere considered (post hoc
analysis). Median times to reach a Hb value$13 g/dL in the control
and EPO arms, respectively, were undetermined and 116 days after
MA conditioning; not deﬁned and 52 days after rhEPO started on
D28 after NMHCT; and undeﬁned and 31 days with rhEPO initiated
on D0 (Figure 2B).
The proportions of complete correctors (achieving 13 g/dL)
before D126 posttransplant were 8.1% in the control arm and 63.1%
in the EPO arm (P , .001). After MA conditioning, complete
correctors were 5.2% and 66.7%, respectively (P , .001). These
proportions were 0% and 63.2%, respectively, when rhEPO was
started on D28 (P, .001); and 16% and 60.9%, respectively, when
rhEPO was started on D0 (P, .001) after NMHCT. The proportion
of complete correctors was not signiﬁcantly different among the 2
rhEPO cohorts after NMHCT.
Secondary end points
The proportions of responders (patients increasing their Hb value
by $2 g/dL) were 25% in the control arm and 73.2% in the EPO
arm, and median times to response were undeﬁned and 42 days,
respectively (P , .001). The proportions of correctors (patients
reaching 12 g/dL) were 22.5% in the control arm and 71.9% in the
EPO arm, and median times to correction were undetermined and
53 days, respectively (P, .001). The difference remained highly
signiﬁcant (P, .001) when only patients with baseline Hb values
,10 g/dL were considered (post hoc analysis). We also analyzed
these end points in each cohort separately: median times to re-
sponse were shorter and proportions of responders or correctors
were higher in patients receiving EPO compared with controls
(Table 2).
The proportions of patients requiring RBC transfusions, as well
as the number of units transfused per patient, were higher in the
control arm compared with the EPO arm (Figure 3A). The difference
remained highly signiﬁcant (P, .001 for proportions of transfused
patients and P5 .017 for the number of transfused units) when only
patientswith baselineHbvalues,10 g/dLwere considered (post hoc
analysis). Analyzing the 3 cohorts separately, we observed only a
trend toward decreased transfusion rates with rhEPO, except when
rhEPO was started on D28 after NMHCT, when the difference was
signiﬁcant (Figure 3B).We also asked whether there was any beneﬁt
to start rhEPO earlier (D0 rather than D28) after NMHCT (post hoc
analysis). There was no signiﬁcant difference between the 2 rhEPO
groups during D0 to D30, D30 to D126, or overall, neither for
proportions of patients transfused nor for numbers of units transfused
per patient (supplemental Figure 1).
Figure 4 displays the evolution of Hb values with the Hb AUC.
Mean Hb levels were higher in the EPO arm from week 2 after
treatment initiation until D180. This was also true in the 3 cohorts
separately.
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Number of patients 19 15 18 19 25 23 62 57
Age (mean 6 SD) 40 6 13 40 6 12 53 6 11 55 6 9 57 6 10 55 6 13 51 6 13 51 6 13
Sex (female/male) 6 / 13 8 / 7 7 / 11 8 / 11 10 / 15 11 / 12 23 / 39 27 / 30
Body weight before transplantation, kg
(mean 6 SD)




12 7 6 6 7 16 25 29
Acute lymphoid leukemia/lymphoblastic
lymphoma
2 3 0 0 0 0 2 3
Non-Hodgkin’s lymphoma 4 3 5 8 7 4 16 15
Hodgkin’s lymphoma 0 0 2 1 1 0 3 1
Multiple myeloma 0 1 4 3 8 3 12 7
Other 1 1 1 1 2 0 4 2
Disease risk index
1 7 7 5 5 3 8 15 20
2 7 4 7 9 13 14 27 27
3 4 3 3 4 7 1 14 8
4 1 1 1 1 2 0 4 2
Not known 0 0 2 0 0 0 2 0
Status at transplantation
First or second complete remission 9 8 5 6 10 13 24 27
First or second partial remission 3 1 4 4 6 5 13 10
Beyond second partial remission 0 1 1 1 0 1 1 3
Refractory disease 4 4 3 3 2 3 9 10
Untreated disease 2 0 4 1 1 0 7 1
Untreated relapse 0 0 1 4 6 1 7 5
Nonmalignant disease 1 1 0 0 0 0 1 1
Conditioning regimens
MA
AraC-Cy-TBI 6 5 0 0 0 0 6 5
AraC-Mel-TBI 4 3 0 0 0 0 4 3
Cy-TBI 4 5 0 0 0 0 4 5
Mel-TBI 1 1 0 0 0 0 1 1
Cy-ATG 2 1 0 0 0 0 2 1
Other 2 0 0 0 0 0 2 0
Non-MA
Fluda-TBI 2Gy 0 0 13 15 17 19 30 34
Fluda-TBI 2x2Gy 0 0 4 2 4 3 8 5
TBI 2Gy 0 0 1 2 3 0 4 2
Fluda-Cy 0 0 0 0 1 1 1 1
Prior HCT
Autologous 0 1 9 7 14 7 23 15
MA allogeneic 1 0 0 0 1 0 2 0
Non-MA allogeneic 0 1 1 3 2 1 3 5
Donor type
HLA-identical sibling 10 10 6 4 8 3 24 17
Other related 2 1 0 1 9 11 11 13
HLA-identical unrelated 3 1 3 9 0 0 6 10
HLA-nonidentical unrelated 4 3 9 5 8 9 21 17
ABO compatibility
Identical 10 7 9 12 14 15 33 34
Major mismatch 5 3 5 6 5 3 15 12
Major and minor mismatch 1 2 2 0 1 3 4 5
Minor mismatch 3 3 2 1 5 2 10 6
Graft manipulation
None 8 4 10 10 24 23 42 37
CD34 selection 7 8 0 0 0 0 7 8
AC133 selection 4 3 0 0 0 0 4 3
CD8 depletion 0 0 8 9 1 0 9 9
AraC, cytarabine; ATG, antithymocyte globulin; Cy, cyclophosphamide; Fluda, fludarabine; Gy, Gray; Mel, melphalan; TBI, total body irradiation.
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After the reticulocyte surge on D21 (engraftment) in the 2
arms, we observed a second reticulocyte peak on D42 to D60 in
EPO-treated patients (Figure 5A). Although the reticulocyte peak
was transient, the sTfR increase was quite sustained (Figure 5B).
Ferritin levels did not differ between the 2 arms, but Tsat de-
creased faster in the EPO arm (P , .05) (Figures 5C-D). The
percentage of hypochromic RBCs (available only in cohort 3)
was signiﬁcantly higher in the EPO arm from D28 until D100
(Figure 5E).
Based on regression equations between Hct and log (Epo),
predicted log (Epo) values were derived for each Hct and O/P
ratios of observed/predicted Epo values were calculated.2 Epo O/P
ratios before treatment were 0.83 6 0.28 and 0.75 6 0.21,
respectively, in the 2 arms, in case of MA transplantation (NS);
0.83 6 0.3 and 0.83 6 0.28 on D28 after NMHCT (NS); and
1.05 6 0.38 and 0.89 6 0.27, respectively, on D0 of NMHCT in
cohort 3 (NS).
All patients received QOL forms, but only a few ﬁlled them in
(52 patients at baseline, 37 at D30 post-rhEPO, 25 at D70, and 15 at
D150). It was therefore not possible to run meaningful comparisons
between the 2 groups, and no signiﬁcant relationship was found
between Hb levels and QOL.
Safety issues
No reaction was reported after rhEPO administration. Only 2 pa-
tients, one in each arm, presented a thromboembolic event. The rates
of arterial hypertension were 8% and 14% in the control and EPO
arms, respectively (NS).
The incidence of infection was similar in the 2 arms. Thirty-two
of 66 patients (48%) in the control arm and 37 of 63 patients (59%)
in the EPO arm experienced at least one infectious episode be-
tween D28 and D126 after HCT (NS). The number of infections per
patient between D28 and D126 (between D0 and D126 in cohort
3) was 0.7 6 0.1 and 0.9 6 0.1 in the control and EPO arms, re-
spectively (NS). We observed more CMV reactivations in the EPO
arm (48% of patients) than in the control arm (33%) (P 5 .0192).
Reactivation rates were 0% vs 9% in CMV2/2 pairs (NS) and 57%
vs 47% in high-risk patients (NS) in the EPO and control arms,
respectively.
Six patients in the control arm and 12 in the EPO arm relapsed on
study (ie, untilD126) (NS),whereas 13 and 7 died, respectively (NS).
In multivariate analyses including the disease risk index, con-
ditioning and treatment arm, only the disease risk index was asso-
ciated with relapse. Seven patients experienced graft rejection: 4 in
the control arm and 3 in the EPO arm (NS).
Functional iron deﬁciencywas observed in 6 patients aroundD30
(N 5 1), 60 (N 5 1), or 100 (N 5 4) posttransplant, all in the EPO
arm (P 5 .0105). These patients received IV iron but most of them
already had a brisk response to rhEPO therapy alone. One patient in
the control arm presented absolute iron deﬁciency but did not receive
any iron.
Finally, rhEPO therapy had no impact on platelet and WBC
counts and differential, nor onC-reactive protein, creatinine value, or
liver function tests.
Discussion
Despite the inadequacyofEpo response to anemia afterMAallogeneic
transplantation, most studies reported disappointing results when
rhEPO was administered at very high doses from D1.10-12 How-
ever, we have shown in 2 pilot trials the potential efﬁcacy of
rhEPO initiated on D35 after MA HCT,13 or after NMHCT.15
The aim of this study was to conﬁrm our previous observations
in a prospective randomized trial, especially because there are no
recommendations about rhEPO use after transplantation in published
guidelines.20,21
Our study is the ﬁrst randomized trial demonstrating that rhEPO
is effective after allogeneic HCT, because 63% of patients
receiving rhEPO vs 8% of controls achieved the primary end point
(completeHb correction) at amedian of 90 days. All other analyses,
including Hb response, Hb correction, and Hb AUC, were
signiﬁcantly in favor of rhEPO. This was true also in subanalysis of
each cohort. This conﬁrms the ﬁndings of our pilot trials after MA
conditioning13 and after NMHCT.15 RhEPO was as efﬁcient after MA
and nonmyeloablative conditioning. Indeed, unlike in our pre-
vious study,5 Epo secretion, assessed by Epo O/P ratios, was low
on D28 posttransplant, not only after MA but also after NMHCT.
This could probably be explained by a higher proportion of
NMHCT patients conditioned with only 2 Gy TBI in our previous
report (50%).
Similar Hb responses have been reported in studies involving
patients undergoing MA and NMHCT and treated with erythropoiesis-
stimulating agents (ESA) for persisting anemia after transplan-
tation.22,23 Another study after NMHCT also showed a positive
impact of rhEPO therapy started on D1.24 Hb response was
preceded by the expansion of erythropoietic activity, as assessed
by sTfR levels, whereas reticulocyte counts were only transiently
increased, as reported in previous trials after HCT.13-15,25 This
parameter has indeed a poor quantitative value in assessing erythroid
response.1,26
RBC transfusion requirements were also reduced, even though
this was only borderline signiﬁcant when the 3 cohorts were ana-



























1/1 3 7 8 5 7 5 18 17
1/2 5 3 2 6 0 3 7 12
2/1 5 2 2 7 9 11 16 20
2/2 6 3 6 1 9 4 21 8
AraC, cytarabine; ATG, antithymocyte globulin; Cy, cyclophosphamide; Fluda, fludarabine; Gy, Gray; Mel, melphalan; TBI, total body irradiation.
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studies published by us13 and another group23 reported similar re-
ductions in transfusion requirements with rhEPO. Other randomized
studies,10-12 except 2 much smaller ones,7,8 failed to demonstrate
a beneﬁt of high-dose IV rhEPO on transfusion requirements, but
rhEPO was started early (on D0) and given only during 4 to
8 weeks when there are very few erythroid precursors in the bone
marrow and a lot of endogenous Epo in the plasma. As aplasia is
shortened, less profound or even sometimes absent, we asked
whether initiating rhEPO on D0 could be effective after NMHCT.
Although our pilot trial after NMHCT suggested decreased trans-
fusion requirements only during the ﬁrst month when rhEPO was
started on D0,15 we could not conﬁrm this in the current study.
Pretransplant Hb levels were inversely correlated with transfusions
requirements after NMHCT,27 but Hb levels before NMHCT did
not differ between treatment arms and cohorts. Of course, the non-
myeloablative cohort starting rhEPO on D0 had higher pre-rhEPO
values because their Hb had not yet decreased after conditioning.
Moreover, transfusion rates were similar in the 2 rhEPO groups
over the whole study period. Therefore, there was no beneﬁt to start
rhEPO on D0 rather than on D28.
Unlike other studies,24 ours did not provide systematic iron sup-
plementation but monitored iron parameters to detect functional iron
deﬁciency (deﬁned by a Tsat ,20%, with adequate ferritin values)
that could impair response to rhEPO,1 and to provide IV iron in a
targeted fashion. However, contrary to what is observed after autol-
ogous HCT,28 very few allogeneic transplant recipients developed
low Tsat and required IV iron, and most already had a brisk Hb
responsewith rhEPOalone. Therefore, hematopoietic response in this
study was related to rhEPO therapy, with little contribution from IV
iron. Because, based on Tsat, functional iron deﬁciency occurred
rarely, the increased percentage of hypochromic RBC observed early
in the EPO arm (Figure 5E) was probably not driven by iron de-
ﬁciency but was related to the high percentage of reticulocytes (quite
parallel in Figure 5A) in response to rhEPO.
Studies in cancer patients have demonstrated that Epo im-
proved QOL mainly when Hb values reached 11 to 12 g/dL.29-31
Unfortunately, collected QOL data were insufﬁcient to draw any
conclusion. More stringent assessments of QOL should be pursued
in further studies.
We did not encounter any toxicity of rhEPO therapy. Neutrophil
and platelet engraftment were not inﬂuenced by rhEPO. Although
meta-analyses have shown an increased risk of thromboembolic
events with ESA in cancer patients,32 their rates were similar in the
2 arms in our trial. During the study, 14 patients (5 vs 9; NS)
presented with arterial hypertension, requiring initiation of or an
increase in antihypertensive medications. Many patients already
had preexisting hypertension because of the effect of calcineurin
inhibitors.33 The rates of infection, acute graft-vs-host disease, or
graft rejection were also similar in the 2 arms. As predicted from its
smaller proportion of patients at low risk for CMV reactivation
(CMV-seronegative donor and recipient), there were more CMV
reactivations in the EPO arm. However, reactivation rates were
similar in both arms among low-risk and high-risk patients analyzed
separately. Meta-analyses have also suggested shortened survival in
cancer patients receiving ESA,34 but not in patients treated with
concurrent chemotherapy.32,34 In our trial, short-term, disease-free,
and overall survivalswere comparable in the 2 arms (if anything, there
were fewer deaths in the EPO arm; NS). Relapse rates were also
similar in the 2 arms, with only the disease risk index being asso-
ciated with relapse in multivariate analyses. However, long-term
Figure 2. Cumulative incidence of complete response (Hb ‡13 g/dL) (primary
end point) from the day of treatment initiation. (A) All conditionings together; (B)
after MA conditioning (Cohort 1), after NMHCT with rhEPO started on D28 (Cohort 2),
and after NMHCT when rhEPO initiated on D0 (Cohort 3). The control arm is
indicated by a solid line, and the EPO arm by a dotted line.
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follow-up studies are needed to deﬁnitively rule out an effect on
relapse and survival.
Our study has some limitations. The most important is the target
Hb value of 13 g/dL. Indeed, current guidelines recommend a target
Hb;12 g/dL20 or the lowest Hb level needed to avoid transfusions21
because of the possible association between high Hb levels and
adverse outcomes. However, during our trial these restrictions were
not yet effective. Thus, to rapidly achieve QOL improvement and
transfusion independence, we aimed at Hb normalization. This is no
longer our policy, even though we did not ﬁnd any difference in
adverse events or deaths in this trial. Conversely, when rhEPO was
started on D28, only 5 patients had a Hb level higher than 11 g/dL
(mean Hb;9 g/dL), in keeping with current guidelines for initiation
of ESA therapy.20,21 In addition, a post hoc analysis limited to pa-
tients with a baseline Hb value ,10 g/dL did not change the
differences between the 2 arms.Nevertheless, even ifwe had adopted
a much lower target Hb such as 9 g/dL, this would not have modiﬁed
the impact of rhEPOon transfusions because their triggerwas 8 g/dL.
Second, although the overall patient population was quite large,
patient numbers were limited in each cohort. Therefore, some could
argue that there may be some undetected heterogeneity in our pop-
ulation for diagnosis, disease stage, conditioning regimen and in-
tensity, donor type, and graft manipulation. However, this was also
the case in all previous studies of rhEPO after HCT, and these
pretransplant characteristics did not signiﬁcantly differ between the
2 arms and did not affect posttransplant erythropoietic activity and
response to rhEPO.13,15
Despite these limitations, our study is the ﬁrst prospective ran-
domized trial to demonstrate rhEPO efﬁcacy in terms of Hb re-
sponses and limitation of transfusions in allogeneic transplantation


















(N 5 23) P value
Hb on the day of rhEPO initiation (mean 6 SD) 9.0 6 1.3 8.8 6 0.8 NS 9.6 6 1.4 9.0 6 1.1 NS 11.1 6 1.9 10.1 6 2.1 NS
Time to Hb $13 g/dL
% achieving (by D126 post-HCT) 5.2 66.7 0 63.2 16.0 60.9
Median (d) after starting rhEPO Undefined 116 ,.001 Undefined 52 ,.001 Undefined 91 ,.001
Time to Hb 1 2 g/dL
% achieving (by D126 post-HCT) 31.6 85.7 11.8 73.7 29.2 65.2
Median (d) after starting rhEPO 189 30 ,.001 307 33 ,.001 Undefined 72 .020
Time to Hb $12 g/dL
% achieving (by D126 post-HCT) 15.8 80.0 11.1 68.4 36.0 69.5
Median (d) after starting rhEPO Undefined 47 ,.001 Undefined 38 .001 Undefined 77 .003
NS, not significant.
Figure 3. Proportions of transfused patients after starting rhEPO. (A) All conditionings together; (B) after MA conditioning (Cohort 1), after NMHCT with rhEPO started on
D28 (Cohort 2), and after NMHCT when rhEPO initiated on D0 (Cohort 3).
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after MA or NMHCT. This successful acceleration of erythroid
recovery compared with previous studies relates to the initiation of
EPO therapy at a more appropriate time frame after transplantation,
ie, when endogenous Epo deﬁciency has become evident and not
at an earlier time point when there are few erythroblasts to respond
and very high serum Epo levels. However, there was no beneﬁt in
Figure 4. Hb levels after transplantation. (A) Hb evolution of all transplants together (P , .001), (B) after MA regimen (Cohort 1), after NMHCT when rhEPO was started on
D28 or D0, respectively (Cohorts 2 and 3). The control arm is indicated by a solid line, and the EPO arm by a dotted line.*P , .05.
Figure 5. Biological parameters after transplan-
tation. Reticulocytes counts (A), sTfR values (B),
ferritin levels (C), transferrin saturation (D), and
percentage of hypochromic RBCs (E) after trans-
plantation (all cohorts together except E [after
NMHCT with rhEPO started on D0]). *P , .05.
40 JASPERS et al BLOOD, 3 JULY 2014 x VOLUME 124, NUMBER 1
initiating treatment earlier, even in the case of NMHCT, thereby
conﬁrming in the setting of NMHCT the previous results after MA
transplantation.
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